Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Cardiology Research

Study Title:  A randomIzed trial coMParing the ELUVIA dRug-elutIng stent versus Zilver PTX stent for treatment of superficiAL femoral and / or proximal popliteal arteries (IMPERIAL) (Identifier: NCT02574481)

Study Purpose:  The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.

Principal Investigator: Mark Burket, MD

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853 


Study Title:  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-M added-on to treprostinil, inhaled (Tyvaso®) in Subjects with Pulmonary Arterial Hypertension (BEAT) (Identifier: NCT01908699)

Study Purpose: Patients new to Tyvaso®, will enter a run-in period on inhaled treprostinil until 90 days of experience is achieved to ensure drug tolerability before enrolling in the study.

Principal Investigator: George Moukarbel, MD

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853 


Study Title: US-based, Observational, Drug Registry Opsumit® (macitentan) new users in clinical practice (OPUS) (Identifier: NCT02126943)

Study Purpose:  Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit® in the post-marketing setting

Principal Investigator: Samer Khouri, M.D.

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853 


Study Title:   A Multicenter, Open-label Extension (OLE) to Assess the Long-term Safety and Efficacy of Evolocumab" (Protocol 20140128)    (Identifier: NCT02304484)

Study Purpose:  The purpose of this study is to characterize the safety and tolerability of long-term administration of evolocumab in subjects with known coronary artery disease and hypercholesterolemia

Principal Investigator: Mujeeb Sheikh, M.D.

Study Coordinator: Stephanie Frank, RN, for more information, please contact 419.383.3853

 

Last Updated: 10/7/16